The closing price of Edwards Lifesciences Corp (NYSE: EW) was $85.22 for the day, up 0.41% from the previous closing price of $84.87. In other words, the price has increased by $+0.35 from its previous closing price. On the day, 3296215 shares were traded. EW stock price reached its highest trading level at $85.74 during the session, while it also had its lowest trading level at $83.61.
Ratios:
Our analysis of EW’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 31.10 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 79.72. For the most recent quarter (mrq), Quick Ratio is recorded 2.40 and its Current Ratio is at 3.38. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
On January 04, 2024, Evercore ISI Downgraded its rating to In-line which previously was Outperform and also lowered its target price recommendation from $80 to $77.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 29 when Ullem Scott B. sold 7,255 shares for $85.59 per share. The transaction valued at 620,923 led to the insider holds 19,074 shares of the business.
GALLAHUE KIERAN sold 3,058 shares of EW for $267,911 on Feb 23. The Director now owns 67,219 shares after completing the transaction at $87.61 per share. On Feb 21, another insider, Chopra Daveen, who serves as the CVP, TMTT of the company, sold 8,200 shares for $86.74 each. As a result, the insider received 711,272 and left with 22,750 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EW now has a Market Capitalization of 51.24B and an Enterprise Value of 50.29B. As of this moment, Edwards’s Price-to-Earnings (P/E) ratio for their current fiscal year is 37.03, and their Forward P/E ratio for the next fiscal year is 27.53. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.00. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.53 while its Price-to-Book (P/B) ratio in mrq is 7.70. Its current Enterprise Value per Revenue stands at 8.38 whereas that against EBITDA is 28.57.
Stock Price History:
Over the past 52 weeks, EW has reached a high of $94.87, while it has fallen to a 52-week low of $60.57. The 50-Day Moving Average of the stock is 79.52, while the 200-Day Moving Average is calculated to be 78.08.
Shares Statistics:
EW traded an average of 4.42M shares per day over the past three months and 3.43M shares per day over the past ten days. A total of 601.10M shares are outstanding, with a floating share count of 591.88M. Insiders hold about 1.57% of the company’s shares, while institutions hold 82.52% stake in the company. Shares short for EW as of Feb 15, 2024 were 10.09M with a Short Ratio of 2.29, compared to 10.87M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.68% and a Short% of Float of 1.69%.
Earnings Estimates
The firm’s stock currently is rated by 24 analysts. On average, analysts expect EPS of $0.64 for the current quarter, with a high estimate of $0.66 and a low estimate of $0.63, while EPS last year was $0.62. The consensus estimate for the next quarter is $0.7, with high estimates of $0.72 and low estimates of $0.67.
Analysts are recommending an EPS of between $2.8 and $2.65 for the fiscal current year, implying an average EPS of $2.75. EPS for the following year is $3.09, with 26 analysts recommending between $3.24 and $2.88.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 23 analysts. It ranges from a high estimate of $1.61B to a low estimate of $1.54B. As of the current estimate, Edwards Lifesciences Corp’s year-ago sales were $1.46B, an estimated increase of 7.90% from the year-ago figure. For the next quarter, 23 analysts are estimating revenue of $1.65B, an increase of 9.40% over than the figure of $7.90% in the same quarter last year. There is a high estimate of $1.68B for the next quarter, whereas the lowest estimate is $1.6B.
A total of 27 analysts have provided revenue estimates for EW’s current fiscal year. The highest revenue estimate was $6.6B, while the lowest revenue estimate was $6.44B, resulting in an average revenue estimate of $6.52B. In the same quarter a year ago, actual revenue was $6B, up 8.60% from the average estimate. Based on 27 analysts’ estimates, the company’s revenue will be $7.16B in the next fiscal year. The high estimate is $7.38B and the low estimate is $6.95B. The average revenue growth estimate for next year is up 9.80% from the average revenue estimate for this year.
